Revolutionizing Type 2 Diabetes Management: The Benefits of Dapagliflozin and Sitagliptin FDC for Effective and Sustainable Care

Understanding Type 2 Diabetes in Indians

Distinct Trajectory of Type 2 Diabetes

Type 2 diabetes among Indians exhibits a unique and aggressive progression characterized by increased insulin resistance, early dysfunction of beta cells, lower body mass index (BMI) thresholds, and an earlier onset of the disease. This distinctive phenotype underscores the need for proactive early intervention.

Importance of Multi-Drug Therapy

To effectively manage hyperglycemia and reduce the risk of cardiovascular and renal complications, a multi-drug therapy approach is essential. This therapy should focus on preserving beta-cell function and protecting cardiovascular and renal health.

Support for Early Intensification

A significant shift in clinical practice has been observed, with over 80% of physicians, including those from India, now advocating for early intensification in the management of Type 2 diabetes.

The Role of Dapagliflozin and Sitagliptin FDC

A Sustainable Early Option

This article explores the evidence backing the fixed-dose combination (FDC) of dapagliflozin and sitagliptin as a viable early treatment option for Type 2 diabetes patients who present with risk factors.

Clinical Impact of Dapagliflozin and Sitagliptin

Dapagliflozin (an SGLT-2 inhibitor) and sitagliptin (a DPP-4 inhibitor) have become increasingly relevant in clinical settings due to their glycemic control and additional pleiotropic benefits.

Evidence Review of Dapagliflozin and Sitagliptin in High CV Risk T2DM

Study Overview

A retrospective study involving 3,112 adult patients with Type 2 diabetes in India evaluated the age-stratified efficacy of the dapagliflozin and sitagliptin FDC. Participants were categorized into three age groups: 18–40, 41–60, and over 60 years.

Findings on Glycemic Control

The primary endpoint analysis focused on 838 patients with baseline HbA1c levels of 8% or higher. Results indicated a significant reduction in HbA1c from 9.29% to 7.98% over three months (a change of −1.31%, p<0.001) across all age groups, with notable improvements in fasting and postprandial glucose levels.

Expert Recommendations

An Indian expert panel has endorsed the dapagliflozin and sitagliptin FDC as a first-line treatment for patients who are new to therapy and exhibit HbA1c levels of 7.5% or higher, particularly those with cardiometabolic risks. This recommendation aligns with the American Diabetes Association’s 2026 guidelines advocating for early combination therapy to expedite glycemic control.

Abbreviations

ADA – American Diabetes Association, ALT – Alanine Aminotransferase, ASCVD – Atherosclerotic Cardiovascular Disease, AST – Aspartate Aminotransferase, BMI – Body Mass Index, BP – Blood Pressure, CKD – Chronic Kidney Disease, CV – Cardiovascular, DPP-4i – Dipeptidyl Peptidase-4 Inhibitor, eGFR – estimated Glomerular Filtration Rate, FBG – Fasting Blood Glucose, FDC – Fixed-Dose Combination, HbA1c – Glycated Hemoglobin, HF – Heart Failure, LoA – Level of Agreement, LVEDD – Left Ventricular End-Diastolic Diameter, LVESD – Left Ventricular End-Systolic Diameter, MACE – Major Adverse Cardiovascular Events, MASLD – Metabolic Dysfunction-Associated Steatotic Liver Disease, NT-proBNP – N-Terminal Pro-B-Type Natriuretic Peptide, PPBG – Postprandial Blood Glucose, RCT – Randomized Controlled Trial, RR – Relative Risk, SGLT-2i – Sodium-Glucose Co-Transporter-2 Inhibitor, T2D/T2DM – Type 2 Diabetes Mellitus, γ-GT – Gamma-Glutamyl Transferase.